<DOC>
	<DOCNO>NCT02989025</DOCNO>
	<brief_summary>The purpose study learn give 17-hydroxyporgesterone caproate ( 17 OHPC ) mother preeclampsia diagnose 34 week gestation improve mother baby outcome .</brief_summary>
	<brief_title>Progesterone Enhance Safety Success Expectantly Managed Preterm Severe/Superimposed Preeclampsia</brief_title>
	<detailed_description>The OBGYN house attend staff duty care patient determine appropriateness study inclusion . Once enrol informed consent , participant randomize assigned Coordinator receive 17 OHPC , 250mg IM equivalent placebo give admission every 7 day thereafter . Blood sample approximately 1-2 teaspoon collect baseline immediately prior administration 17 OHPC placebo , 24 hour ( +-2hrs ) . After first 24 hour , blood sample collect every 72 hr delivery 24hrs ( +- 2hrs ) delivery . Placentas collect delivery investigator also collect information mother newborn hospital discharge include de-identified routine ultrasound .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>UMMC antepartum patient preterm PE 23 0/7ths 33 0/7ths week gestation initially evaluate Willing able understand study procedure provide inform consent &gt; 33 week gestational age &lt; 23 week gestation Maternal compromise require emergent delivery ( ongoing placental abruption , DIC , pulmonary edema ) . Fetal compromise require emergent delivery ( fetal bradycardia , recurrent late fetal heart rate deceleration , minimal absent fetal heart rate variability ) . Parameters accord current practice guideline exclude patient expectant management include follow : Preterm premature rupture membrane ( PPROM ) &gt; 34 week gestation ; Platelet count &lt; 100,000/microliter ( thrombocytopenia ) evidence HELLP syndrome ; Persistently abnormal hepatic enzyme concentration ( twice upper normal value ) ; Severe fetal growth restriction ( ultrasoundestimated fetal weight less fifth percentile ) ; Severe Oligohydramnios ( AFI &lt; 5cm ) Reversal end diastolic flow ( REDF ) umbilical artery Doppler testing ; New onset renal dysfunction increase renal dysfunction ( serum creatinine &gt; 1.1 mg/dL ; Recurrent ( &gt; 2 reading &gt; 30 minute apart ) severe hypertension despite antihypertensive therapy ; Eclampsia ; Pulmonary edema ; Abruption placenta ; Nonreassuring fetal status daily testing ( biophysical profile &lt; 4/10 and/or recurrent variable late deceleration ) ; IUFD</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>